11.03.21
Nutraceutical supplier Ingredients By Nature (IBN) recently received patent approval by the USPTO for a second patent for Eriomin, an eriocitrin extract.
The eriocitrin patent claim is stated as a “method of increasing GLP-1 levels in a subject in need thereof, comprising administering a composition comprising eriocitrin to the subject.”
GLP-1 helps the body to maintain appropriate amounts of insulin secretion and glucose uptake. The patent further solidifies the use of eriocitrin to support healthy fasting blood glucose, such as in prediabetics, by administering 50-600 mg of the citrus flavonoid for increased GLP-1 levels. This news comes in addition to an amendment made on a prior Eriomin patent, which changed the dosage claim of eriocitrin from 100-200 mg to 25-800 mg for the lowering of glucose levels.
“There are multiple facets to prediabetes management and increasing GLP-1 plays a vital role in helping to support healthy blood glucose levels,” Rob Brewster, president of IBN, said. “The approval of our second eriocitrin patent provides strong support for our efforts to raise awareness of the flavonoid’s multi-faceted potential. We also have several more very promising human clinicals in process and hope to see some of them published soon.”
Currently, two forms of Eriomomin are available – Eriomin Glucose for prediabetes management and Eriomin Esport for gaming-related health concerns, by supporting blood glucose levels within the normal range. IBN will be conducting more research that investigates Eriomin’s benefits for both these categories and others over the coming years, the company said.
The eriocitrin patent claim is stated as a “method of increasing GLP-1 levels in a subject in need thereof, comprising administering a composition comprising eriocitrin to the subject.”
GLP-1 helps the body to maintain appropriate amounts of insulin secretion and glucose uptake. The patent further solidifies the use of eriocitrin to support healthy fasting blood glucose, such as in prediabetics, by administering 50-600 mg of the citrus flavonoid for increased GLP-1 levels. This news comes in addition to an amendment made on a prior Eriomin patent, which changed the dosage claim of eriocitrin from 100-200 mg to 25-800 mg for the lowering of glucose levels.
“There are multiple facets to prediabetes management and increasing GLP-1 plays a vital role in helping to support healthy blood glucose levels,” Rob Brewster, president of IBN, said. “The approval of our second eriocitrin patent provides strong support for our efforts to raise awareness of the flavonoid’s multi-faceted potential. We also have several more very promising human clinicals in process and hope to see some of them published soon.”
Currently, two forms of Eriomomin are available – Eriomin Glucose for prediabetes management and Eriomin Esport for gaming-related health concerns, by supporting blood glucose levels within the normal range. IBN will be conducting more research that investigates Eriomin’s benefits for both these categories and others over the coming years, the company said.
